(Q48471800)

11 February 2018

title

The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites (English)

1 reference

11 February 2018

author

Kristian Linnet

series ordinal

3

1 reference

11 February 2018

author name string

Thomas Broeng Ejsing

series ordinal

1

1 reference

11 February 2018

Jørgen Hasselstrøm

series ordinal

2

1 reference

11 February 2018

publication date

1 January 2006

1 reference

11 February 2018

Drug Metabolism and Drug Interactions

published in

1 reference

11 February 2018

volume

21

1 reference

11 February 2018

issue

3-4

1 reference

11 February 2018

page(s)

139-162

1 reference

11 February 2018

Variable modulation of opioid brain uptake by P-glycoprotein in mice

cites work

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Methadone--metabolism, pharmacokinetics and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

In vitro P-glycoprotein affinity for atypical and conventional antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

The physiological function of drug-transporting P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Tissue distribution and chemical induction of multiple drug resistance genes in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

Role of P-glycoprotein in pharmacokinetics: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FDMDI.2006.21.3-4.139

10.1515/DMDI.2006.21.3-4.139

21 January 2018

Identifiers

DOI

1 reference

11 February 2018

1 reference

11 February 2018